Pharma regulatory workloads are now outpacing company growth, fuelling investment in AI-boosted regulatory process automation. ArisGlobal’s director of product management’s Agnes Cwienczek, reports on these and other top-level findings from a new Censuswide survey of senior life sciences regulatory professionals.
A new survey from Censuswide with 100 senior regulatory professionals in US pharma and biopharma organisations, confirms that regulatory obligations have soared over the last five years, with three in five (60%) saying the scale of increase is far beyond that of normal company growth - a trend set to continue over the next five years.